Association of Peripheral Norepinephrine Protocol Implementation on Central Venous Catheter Placement in a Medical ICU

IF 2.7
CHEST critical care Pub Date : 2025-12-01 Epub Date: 2025-07-21 DOI:10.1016/j.chstcc.2025.100195
Lara M. Groetzinger PharmD, BCCCP , Julia Williams MSN, RN, CCRN , Susan Svec MSN, RN, CCRN , Michael P. Donahoe MD , Phillip E. Lamberty MD , Ian J. Barbash MD
{"title":"Association of Peripheral Norepinephrine Protocol Implementation on Central Venous Catheter Placement in a Medical ICU","authors":"Lara M. Groetzinger PharmD, BCCCP ,&nbsp;Julia Williams MSN, RN, CCRN ,&nbsp;Susan Svec MSN, RN, CCRN ,&nbsp;Michael P. Donahoe MD ,&nbsp;Phillip E. Lamberty MD ,&nbsp;Ian J. Barbash MD","doi":"10.1016/j.chstcc.2025.100195","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Central venous catheters (CVCs) are associated with significant morbidity, mortality, and costs in the ICU. One strategy to reduce CVC complications is to avoid placing them altogether. Although norepinephrine (NE) is typically administered via a CVC, data increasingly suggest it may be safely administered via peripheral IV lines.</div></div><div><h3>Research Question</h3><div>Can protocolized administration of peripheral NE decrease CVC utilization?</div></div><div><h3>Study Design and Methods</h3><div>We implemented a protocol using peripheral IVs to administer NE infusion in our medical ICU (MICU) in March 2019. To determine the impact of our protocol on CVC placement, we compared the proportion of MICU patients who received a CVC before (July 1, 2017, to February 28th, 2019) and after (March 1, 2019 to December 31, 2023) protocol implementation. We then compared the change in CVC utilization in the MICU with that in all other ICUs in the same hospital from 2017 to 2023. We also evaluated the percentage of patients receiving the peripheral infusion who ultimately did not require a CVC during their index MICU stay.</div></div><div><h3>Results</h3><div>The average proportion of MICU patients who received a CVC decreased significantly after protocol initiation: pre, 59.5% vs post, 53.5%, <em>P</em> &lt; .01. Central line utilization in the control ICUs remained consistent over the same period, with 60.5% in the pre-intervention period and 61.5% in the postintervention period (<em>P</em> = .34). In the MICU postintervention period, there were 819 peripheral NE infusions, with 391 (47.4%) never receiving a CVC during their index MICU stay. Nine patients (1.1%) received extravasation treatment.</div></div><div><h3>Interpretation</h3><div>Implementation of a protocol using peripherally infused NE was found to be safe, feasible, and associated with a decrease CVC utilization over time. Our study provides further evidence that many patients prescribed NE do not require a central line, and protocolized administration can decrease the use of CVCs on a broader scale.</div></div>","PeriodicalId":93934,"journal":{"name":"CHEST critical care","volume":"3 4","pages":"Article 100195"},"PeriodicalIF":2.7000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CHEST critical care","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949788425000681","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/21 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Central venous catheters (CVCs) are associated with significant morbidity, mortality, and costs in the ICU. One strategy to reduce CVC complications is to avoid placing them altogether. Although norepinephrine (NE) is typically administered via a CVC, data increasingly suggest it may be safely administered via peripheral IV lines.

Research Question

Can protocolized administration of peripheral NE decrease CVC utilization?

Study Design and Methods

We implemented a protocol using peripheral IVs to administer NE infusion in our medical ICU (MICU) in March 2019. To determine the impact of our protocol on CVC placement, we compared the proportion of MICU patients who received a CVC before (July 1, 2017, to February 28th, 2019) and after (March 1, 2019 to December 31, 2023) protocol implementation. We then compared the change in CVC utilization in the MICU with that in all other ICUs in the same hospital from 2017 to 2023. We also evaluated the percentage of patients receiving the peripheral infusion who ultimately did not require a CVC during their index MICU stay.

Results

The average proportion of MICU patients who received a CVC decreased significantly after protocol initiation: pre, 59.5% vs post, 53.5%, P < .01. Central line utilization in the control ICUs remained consistent over the same period, with 60.5% in the pre-intervention period and 61.5% in the postintervention period (P = .34). In the MICU postintervention period, there were 819 peripheral NE infusions, with 391 (47.4%) never receiving a CVC during their index MICU stay. Nine patients (1.1%) received extravasation treatment.

Interpretation

Implementation of a protocol using peripherally infused NE was found to be safe, feasible, and associated with a decrease CVC utilization over time. Our study provides further evidence that many patients prescribed NE do not require a central line, and protocolized administration can decrease the use of CVCs on a broader scale.
外周去甲肾上腺素方案实施与内科ICU中心静脉置管的关系
中心静脉导管(CVCs)在ICU中与显著的发病率、死亡率和成本相关。减少CVC并发症的一个策略是避免将它们全部放置。虽然去甲肾上腺素(NE)通常通过CVC给药,但越来越多的数据表明,通过外周静脉滴注可以安全给药。研究问题:外周NE的程序化管理是否会降低CVC利用率?研究设计和方法我们于2019年3月在我们的医学ICU (MICU)实施了一项使用外周静脉输注NE的方案。为了确定我们的方案对CVC放置的影响,我们比较了方案实施前(2017年7月1日至2019年2月28日)和实施后(2019年3月1日至2023年12月31日)接受CVC的MICU患者比例。然后,我们比较了2017年至2023年MICU与同一医院所有其他icu CVC利用率的变化。我们还评估了接受外周输注的患者在MICU住院期间最终不需要CVC的百分比。结果MICU患者接受CVC的平均比例在方案启动后显著下降:方案启动前为59.5%,方案启动后为53.5%,P < 01。对照组icu的中心静脉使用率同期保持一致,干预前为60.5%,干预后为61.5% (P = 0.34)。在干预后的MICU期间,有819例外周NE输注,其中391例(47.4%)在其索引MICU期间从未接受过CVC。外渗治疗9例(1.1%)。研究发现,使用外设注入的NE实现协议是安全、可行的,并且随着时间的推移与CVC利用率的降低有关。我们的研究提供了进一步的证据,证明许多患者不需要中央静脉导管,并且协议化的给药可以在更大范围内减少cvc的使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CHEST critical care
CHEST critical care Critical Care and Intensive Care Medicine, Pulmonary and Respiratory Medicine
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书